• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Precision medicine using patient-derived organoid of pancreatic cancer

Research Project

Project/Area Number 21K07957
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionThe University of Tokyo

Principal Investigator

Saito Tomotaka  東京大学, 医学部附属病院, 助教 (10815781)

Co-Investigator(Kenkyū-buntansha) 宮林 弘至  東京大学, 医学部附属病院, 助教 (50634961)
伊地知 秀明  東京大学, 医学部附属病院, 講師 (70463841)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2021: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords膵癌 / オルガノイド / 個別化医療 / プレシジョンメディシン
Outline of Research at the Start

膵癌は依然として最難治癌であり、遺伝子情報に基づくプレシジョン医 療が膵癌においても試されていが、膵癌では治療標的となる遺伝子変異が乏しいこと、豊富な間質と腫瘍の相互作用により治療抵抗性を示すことなどの問題もある。膵癌患者由来オルガノイドは膵癌の病態を理解するための強力なツールであり、薬剤スクリーニングと遺伝子発現解析から薬剤感受性シグナチャーによるプレシジョン医療を提唱すると共に、オルガノイドの3次元培養と移植マウスモデル、患者の薬剤感受性の違いから薬剤耐性のメカニズムや腫瘍間質相互作用の解析を行い、新規治療戦略の開発につながる研究を目指す。

Outline of Final Research Achievements

The aim of this study was to establish a drug screening platform using patient-derived organoids (PDOs) from pancreatic cancer. We successfully established 30 PDOs from needle biopsy specimens of pancreatic cancer patients, and drug screening was conducted on 20 of these PDOs. Sensitivity to five drugs commonly used in pancreatic cancer treatment (gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, and paclitaxel) was determined, revealing differences in drug sensitivity depending on the type of PDO. Additionally, screening of molecular targeted drugs was performed on three PDOs, yielding similar results. This research is believed to contribute to the development of novel therapeutic strategies for the challenging cancer, pancreatic cancer. Further studies are warranted for potential clinical applications in the future.

Academic Significance and Societal Importance of the Research Achievements

膵癌は難治癌であり、効果的な治療戦略の開発が望まれる。本研究では膵癌患者より得られた検体からオルガノイドを樹立し、薬剤感受性を調べることで、治療戦略に役立てるプラットフォーム作成を目的とした。オルガノイドを30株樹立に成功し、そのうちの20株に対して薬剤試験を施行可能であり、有用な結果を得た。今後、臨床応用にむけてさらなる研究が望まれる。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (1 results)

All 2023

All Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results)

  • [Journal Article] A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer2023

    • Author(s)
      Hye-Been Yoo, Jin Woo Moon , Hwa-Ryeon Kim, Hee Seung Lee, Koji Miyabayashi, Chan Hee Park, Sabrina Ge, Amy Zhang, Yoo Keung Tae, Yujin Sub, Hyun-Woo Park, Heon Yung Gee, Faiyaz Notta, David A Tuveson, Seungmin Bang, Mi-Young Kim, Jae-Seok Roe
    • Journal Title

      Gastroenterology

      Volume: 165 Issue: 1 Pages: 133-148

    • DOI

      10.1053/j.gastro.2023.02.049

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi